Clinical Characteristics of Patients with Diabetes 2 Usually Treated in a Specialized Clinic, from the NEA/SAD Chapter

Claudia Karina Koleff; Jorgelina Valeria Llense; Sandra Kremmer; Monica de la Cruz; Verónica de la Vega; Solis Gustavo; Ruiz Diaz Daniel; María Cielo Frisone; Maria Celia Diaz; Laura Martinez; Irene Ojeda Damico; Gabriela Alegre; Elizabeth Mendez; Elida Beatriz Romero; Teresita Sosa Cabral; Medeot Rech Maité

doi:doi:10.11648/j.ijcems.20220802.12

Clinical Characteristics of Patients with Diabetes 2 Usually Treated in a Specialized Clinic, from the NEA/SAD Chapter

Claudia Karina Koleff, Jorgelina Valeria Llense, Sandra Kremmer, Monica de la Cruz, Verónica de la Vega, Solis Gustavo, Ruiz Diaz Daniel, María Cielo Frisone, Maria Celia Diaz, Laura Martinez, Irene Ojeda Damico, Gabriela Alegre, Elizabeth Mendez, Elida Beatriz Romero, Teresita Sosa Cabral, Medeot Rech Maité

Published in International Journal of Clinical and Experimental Medical Sciences (Volume 8, Issue 2)

Received: 12 March 2022 Accepted: 6 April 2022 Published: 26 April 2022

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

Introduction: Diabetes is a public health problem. The need arises to know the clinical situation and pharmacological treatment of type 2 diabetic patients, in the Diabetes clinic of the different provinces that constitute the NEA /SAD chapter. Objectives: In patients with Diabetes 2, attended in NEA clinics, in: December 2019, January and February 2020: To know: - sex. - Average age – Evolution time and family history in first degree, of Diabetes. - Metabolic control by HbA1c (last 2). -Pharmacological treatment and self-monitoring. - Cancer frequency and location. - Presence of: Risk factors (Overweight / Obesity, hypertension, dyslipemia, hyperuricemia) and treatment. Chronic complications. Materials and Methods: Observational, descriptive, transversal and prospective study. Consecutive sample of patients with Diabetes 2, > 18 years. Criteria: Inclusion: More than one year of diagnosis and attendance at the clinic. Exclusion: Acute intercurrences. Data were loaded into a spreadsheet. Descriptive analysis of the variables was performed. Results: 888 patients. Average age 58 years. Female 465 (52%), Male 423 (48%). Years of diagnosis: <5: 248 (28%), 5 to 10: 338 (38%), > 10: 302 (34%). Family history: YES 445 (50%). HbA1c: <7% good: 317 (36%), 7.01 to 8% regular: 328 (37%), >8% bad: 243 (27%). Medication: Insulin: 142 (16%), Oral drugs plus insulin: 226 (25%), Oral drugs: 520 (59%); single drug; 214 (24%), combined; 306 (35%). Self-monitoring: NO: 165 (19%). Cancer: NO: 870 (98%). Normal weight: 256 (29%). Hypertension: YES: 641 (72.1%), treated yes: 558 (62.8%), no 83 (9.3%). Dyslipemias: YES: 475 (53%), treated yes: 342 (38.5%), no 133 (15%). Hyperuricemia: NO: 784 (88.3%). Cardiovascular disease: NO: 667 (75%). Retinopathy: NO: 650 (73%). Peripheral neuropathy: NO: 667 (75.1%). Nephropathy: NO: 685 (77.1%). Conclusions: Of the patients evaluated, most are women, average age 58. More than 5 years of diagnosis, with family history. Good to regular metabolic control. Treated with oral drugs, they perform self-monitoring. With risk factors, mostly treated. More than 70% do not present cardiovascular disease or microangiopathic complications. Cancer in 2%, being of breast, more frequent.

Published in	International Journal of Clinical and Experimental Medical Sciences (Volume 8, Issue 2)
DOI	10.11648/j.ijcems.20220802.12
Page(s)	24-31
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2022. Published by Science Publishing Group

Keywords

Type 2 Diabetes, Clinical Features, Chronic Complications, Risk Factors

References

[1]	Cuarta Encuesta Nacional de factores de riesgo 2018. Fourth National Survey of risk factors 2018. Dirección Nacional de Promoción de la Salud y Control de Enfermedades Crónicas no transmisibles. Ministerio de salud y desarrollo social, presidencia de la Nación Argentina. Autoridades ministerio de salud y desarrollo social.
[2]	Fazio L, Toloza C, Pignatta A, Letjman R, Ciancaglini M, Estudio “urku miski”: prevalencia de diabetes mellitus y síndrome metabólico en Antofagasta de la Sierra, población catamarqueña a 3440 metros de altura sobre el nivel del mar, prevalence of diabetes mellitus and metabolic syndrome in Antofagasta de la Sierra, a population of Catamarca at 3440 meters above sea level Revista SAD 2011; 45 (2): 69-77.
[3]	The InterAct Consortium, Long-Term Risk of Incident Type 2 Diabetes and Measures of Overall and Regional Obesity: The EPIC Inter Act Case-Cohort Study, PLOS Medicine 2012; 9 (6): e1001-230.
[4]	Tesfaye, Boulton AJM, Dyck PJ, Freeman R, Horowitz M, Kempler P, Lauria G, Malik RA, Spallone V, Vinik A, Bernardi L, Valensi P, on behalf of the Toronto Diabetic Neuropathy Expert Group, Diabetic Neuropathies: Update on Definitions, Diagnostic Criteria, Estimation of Severity and Treatments, Diabetes Care 2010; 33: 2285–2293.
[5]	Boon How Chew, Sazlina Shariff Ghazali, Mastura Ismail, Jamaiyah Haniff, Mohd Adam Bujang, Age ≥60 years was an independent risk factor for diabetes-related complications despite good control of cardiovascular risk factors in patients with type 2 diabetes mellitus, Experimental Gerontology 2013; 48: 485–491.
[6]	Guías ALAD sobre el Diagnóstico, Control y Tratamiento de la Diabetes Mellitus Tipo 2 con Medicina Basada en Evidencia Edición 2019. ALAD Guidelines on the Diagnosis, Control and Treatment of Type 2 Diabetes Mellitus with Evidence-Based Medicine 2019 Edition, Revista de la ALAD. Comité ejecutivo 2016/2019.
[7]	Commendatore V, Linari M, Dieuzeide G, Ferraro M, Lapertosa S, Puchulu F, Waitman J, Cagide A, Elbert A, Evangelista P, Fuente G, Gheggi M, Giorgini D, Libman A, Lijteroff G, López C, Ozuna B, Prez J, Tonietti M, Traversa M, Costa Gil J. Documento de Opiniones y Recomendaciones Automonitoreo y Monitoreo de Glucosa y Cetonas en la persona con diabetes, Document of Opinions and Recommendations Self-monitoring and Monitoring of Glucose and Ketones in people with diabetes, 2010; 1-37.
[8]	Mc Andrew LM, Napolitano MA, Pogach LM, Quigley KS, Shantz KL, Vander Veur SS, Foster GD, El impacto de la auto monitorización de la glucosa en sangre en una intervención conductual de pérdida de peso para los pacientes con diabetes tipo 2, The impact of blood glucose self-monitoring in a behavioral weight loss intervention for people with type 2 diabetes, Rev. Diabetes Educator 2013; 39 (3): 397-405.
[9]	Kempf K, Tankova T, Martin S, ROSSO en praxi internacional: efectos a largo plazo de autocontrol de la glucosa en sangre para el Control glucometabólico en pacientes con diabetes mellitus tipo 2 no tratados con insulina, Long-Term Effects of Blood Glucose Self-Monitoring for Glycometabolic Control in Patients With Type 2 Diabetes Mellitus Not Treated With Insulin, Rev. Diabetes Tecnología y Terapéutica 2013; 15 (1): 89-96.
[10]	Forman Qi, Jensen J P, Flint M K, Curhan A, Rimm G, Hu E, Qi L. Genetic predisposition to high blood pressure associates with cardiovascular complications among patients with type 2 diabetes: two independent studies, Diabetes 2012; 61 (11): 3026-32.
[11]	F. Arrieta, J. Pedro-Botet, P. Iglesias et al., Diabetes mellitus y riesgo cardiovascular: actualización de las recomendaciones del Grupo de Trabajo de Diabetes y Enfermedad Cardiovascular de la Sociedad Española de Diabetes (SED, 2021), Clínica e Investigación en Arteriosclerosis. Diabetes Mellitus and cardiovascular risk: update of the recommendations of the Diabetes and Cardiovascular Disease Working Group of the Spanish Diabetes Society (SED, 2021), Clinic and Research in Arteriosclerosis.
[12]	D König D. Berg A, Bewegung als Therapie bei Diabetes mellitus Typ 2, Internist 2012; 53: 678–687.
[13]	Malmberg K, Ryde´n L, Wedel H, Birkeland K, Bootsma A, Dickstein K, Efendic S, Fisher M, Hamsten A, Herlitz A, HildebrandtK, MacLeod M., Laakso C. Torp-Pedersen and Waldenstrom for the DIGAMI 2 Investigators, Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity, European Heart Journal 2005; 26: 650–661.
[14]	Tomkin G H, Targets for Intervention in Dyslipidemia in Diabetes, Diabetes Care 2008; 31 (2): S241–S248.
[15]	Edoardo Mannucci, Ilaria Dicembrini, Angelo Lauria, Paolo Pozzilli, Is Glucose Control Important for Prevention of Cardiovascular Disease In Diabetes? Diabetes Care 2013; 36 (2): 259-263.
[16]	Ivan TKA, Cardiovascular Importance of Hyperglycemia and Hypoglycemia, Diabetes Care 2013; 36 (2): 267-271.
[17]	Calvagno M, Prevención, diagnóstico, seguimiento y tratamiento del pie diabético, Prevention, diagnosis, monitoring and treatment of diabetic foot, Rev. SAD 2012; 46 (1): 5-6.
[18]	Emily J. Gallagher et al, Epidemiology and Molecular Mechanisms Tying Obesity, Diabetes, and the Metabolic Syndrome with Cancer, Diabetes Care 2013; 36 (2): 233-239.
[19]	Philip Home, Insulin Therapy and Cancer, Diabetes Care, 2013; 36 (2): 240-244.
[20]	Dara Hope Cohen and Derek LeRoith, Obesity, type 2 diabetes, and cancer: the insulin and IGF connection, Endocrine-Related Cancer 2012; 19: F27–F45.
[21]	XII Jornadas del comité de Graduados de la SAD, Coordinación General: Dra. Cristina Rondoletti Secretaria General: Dra. María Elena Rodríguez, Tema: Cáncer y Diabetes, XII Conference of the SAD Graduates Committee, General Coordination: Dr. Cristina Rondoletti General Secretary: Dr. María Elena Rodríguez, Topic: Cancer and Diabetes, Rev. SAD 2010; 44 (3): 174-207.
[22]	Eeg Olofsson, K.; Cederholm, J.; Nilsson, P. M.; Zethelius, B.; Svensson, A. M.; Gudbjornsdottir, S.; Eliasson, B., New aspects of HbA1c as a risk factor for cardiovascular diseases in type 2 diabetes: an observational study from the Swedish National Diabetes Register (NDR), Rev. Journal of Internal Medicine 2010; 268 (5): 471–482.
[23]	Mingyuan Wu Timothy J. Lyons, Treatment Approaches for Diabetes and Dyslipidemia, Horm Res Paediatr 2011; 76 (1): 76–80.
[24]	Fredrick L. Dunn, Management of dyslipidemia in people with type 2 diabetes mellitus, Rev Endocr Metab Disord 2010; 11: 41–51.
[25]	Sarah Stark Casagrande, Judith E. Fradkin, Sharon H. Saydah, Keith F. Rust, Catherine C. Cowie, The Prevalence of Meeting A1C, Blood Pressure, and LDL Goals Among People With Diabetes, 1988–2010, Diabetes Care 2013; 36: 2271–2279.
[26]	Comité de nefropatía diabética de la SAD, Obesidad y Enfermedad renal, SAD Diabetic Nephropathy Committee, Obesity and Kidney Disease, Rev. SAD 2010; 44 (3): 142-173.

Cite This Article

Plain Text BibTeX RIS

APA Style

Claudia Karina Koleff, Jorgelina Valeria Llense, Sandra Kremmer, Monica de la Cruz, Verónica de la Vega, et al. (2022). Clinical Characteristics of Patients with Diabetes 2 Usually Treated in a Specialized Clinic, from the NEA/SAD Chapter. International Journal of Clinical and Experimental Medical Sciences, 8(2), 24-31. https://doi.org/10.11648/j.ijcems.20220802.12

Copy | Download

ACS Style

Claudia Karina Koleff; Jorgelina Valeria Llense; Sandra Kremmer; Monica de la Cruz; Verónica de la Vega, et al. Clinical Characteristics of Patients with Diabetes 2 Usually Treated in a Specialized Clinic, from the NEA/SAD Chapter. Int. J. Clin. Exp. Med. Sci. 2022, 8(2), 24-31. doi: 10.11648/j.ijcems.20220802.12

Copy | Download

AMA Style

Claudia Karina Koleff, Jorgelina Valeria Llense, Sandra Kremmer, Monica de la Cruz, Verónica de la Vega, et al. Clinical Characteristics of Patients with Diabetes 2 Usually Treated in a Specialized Clinic, from the NEA/SAD Chapter. Int J Clin Exp Med Sci. 2022;8(2):24-31. doi: 10.11648/j.ijcems.20220802.12

Copy | Download

@article{10.11648/j.ijcems.20220802.12,
  author = {Claudia Karina Koleff and Jorgelina Valeria Llense and Sandra Kremmer and Monica de la Cruz and Verónica de la Vega and Solis Gustavo and Ruiz Diaz Daniel and María Cielo Frisone and Maria Celia Diaz and Laura Martinez and Irene Ojeda Damico and Gabriela Alegre and Elizabeth Mendez and Elida Beatriz Romero and Teresita Sosa Cabral and Medeot Rech Maité},
  title = {Clinical Characteristics of Patients with Diabetes 2 Usually Treated in a Specialized Clinic, from the NEA/SAD Chapter},
  journal = {International Journal of Clinical and Experimental Medical Sciences},
  volume = {8},
  number = {2},
  pages = {24-31},
  doi = {10.11648/j.ijcems.20220802.12},
  url = {https://doi.org/10.11648/j.ijcems.20220802.12},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijcems.20220802.12},
  abstract = {Introduction: Diabetes is a public health problem. The need arises to know the clinical situation and pharmacological treatment of type 2 diabetic patients, in the Diabetes clinic of the different provinces that constitute the NEA /SAD chapter. Objectives: In patients with Diabetes 2, attended in NEA clinics, in: December 2019, January and February 2020: To know: - sex. - Average age – Evolution time and family history in first degree, of Diabetes. - Metabolic control by HbA1c (last 2). -Pharmacological treatment and self-monitoring. - Cancer frequency and location. - Presence of: Risk factors (Overweight / Obesity, hypertension, dyslipemia, hyperuricemia) and treatment. Chronic complications. Materials and Methods: Observational, descriptive, transversal and prospective study. Consecutive sample of patients with Diabetes 2, > 18 years. Criteria: Inclusion: More than one year of diagnosis and attendance at the clinic. Exclusion: Acute intercurrences. Data were loaded into a spreadsheet. Descriptive analysis of the variables was performed. Results: 888 patients. Average age 58 years. Female 465 (52%), Male 423 (48%). Years of diagnosis:  10: 302 (34%). Family history: YES 445 (50%). HbA1c: 8% bad: 243 (27%). Medication: Insulin: 142 (16%), Oral drugs plus insulin: 226 (25%), Oral drugs: 520 (59%); single drug; 214 (24%), combined; 306 (35%). Self-monitoring: NO: 165 (19%). Cancer: NO: 870 (98%). Normal weight: 256 (29%). Hypertension: YES: 641 (72.1%), treated yes: 558 (62.8%), no 83 (9.3%). Dyslipemias: YES: 475 (53%), treated yes: 342 (38.5%), no 133 (15%). Hyperuricemia: NO: 784 (88.3%). Cardiovascular disease: NO: 667 (75%). Retinopathy: NO: 650 (73%). Peripheral neuropathy: NO: 667 (75.1%). Nephropathy: NO: 685 (77.1%). Conclusions: Of the patients evaluated, most are women, average age 58. More than 5 years of diagnosis, with family history. Good to regular metabolic control. Treated with oral drugs, they perform self-monitoring. With risk factors, mostly treated. More than 70% do not present cardiovascular disease or microangiopathic complications. Cancer in 2%, being of breast, more frequent.},
 year = {2022}
}

Copy | Download

TY  - JOUR
T1  - Clinical Characteristics of Patients with Diabetes 2 Usually Treated in a Specialized Clinic, from the NEA/SAD Chapter
AU  - Claudia Karina Koleff
AU  - Jorgelina Valeria Llense
AU  - Sandra Kremmer
AU  - Monica de la Cruz
AU  - Verónica de la Vega
AU  - Solis Gustavo
AU  - Ruiz Diaz Daniel
AU  - María Cielo Frisone
AU  - Maria Celia Diaz
AU  - Laura Martinez
AU  - Irene Ojeda Damico
AU  - Gabriela Alegre
AU  - Elizabeth Mendez
AU  - Elida Beatriz Romero
AU  - Teresita Sosa Cabral
AU  - Medeot Rech Maité
Y1  - 2022/04/26
PY  - 2022
N1  - https://doi.org/10.11648/j.ijcems.20220802.12
DO  - 10.11648/j.ijcems.20220802.12
T2  - International Journal of Clinical and Experimental Medical Sciences
JF  - International Journal of Clinical and Experimental Medical Sciences
JO  - International Journal of Clinical and Experimental Medical Sciences
SP  - 24
EP  - 31
PB  - Science Publishing Group
SN  - 2469-8032
UR  - https://doi.org/10.11648/j.ijcems.20220802.12
AB  - Introduction: Diabetes is a public health problem. The need arises to know the clinical situation and pharmacological treatment of type 2 diabetic patients, in the Diabetes clinic of the different provinces that constitute the NEA /SAD chapter. Objectives: In patients with Diabetes 2, attended in NEA clinics, in: December 2019, January and February 2020: To know: - sex. - Average age – Evolution time and family history in first degree, of Diabetes. - Metabolic control by HbA1c (last 2). -Pharmacological treatment and self-monitoring. - Cancer frequency and location. - Presence of: Risk factors (Overweight / Obesity, hypertension, dyslipemia, hyperuricemia) and treatment. Chronic complications. Materials and Methods: Observational, descriptive, transversal and prospective study. Consecutive sample of patients with Diabetes 2, > 18 years. Criteria: Inclusion: More than one year of diagnosis and attendance at the clinic. Exclusion: Acute intercurrences. Data were loaded into a spreadsheet. Descriptive analysis of the variables was performed. Results: 888 patients. Average age 58 years. Female 465 (52%), Male 423 (48%). Years of diagnosis:  10: 302 (34%). Family history: YES 445 (50%). HbA1c: 8% bad: 243 (27%). Medication: Insulin: 142 (16%), Oral drugs plus insulin: 226 (25%), Oral drugs: 520 (59%); single drug; 214 (24%), combined; 306 (35%). Self-monitoring: NO: 165 (19%). Cancer: NO: 870 (98%). Normal weight: 256 (29%). Hypertension: YES: 641 (72.1%), treated yes: 558 (62.8%), no 83 (9.3%). Dyslipemias: YES: 475 (53%), treated yes: 342 (38.5%), no 133 (15%). Hyperuricemia: NO: 784 (88.3%). Cardiovascular disease: NO: 667 (75%). Retinopathy: NO: 650 (73%). Peripheral neuropathy: NO: 667 (75.1%). Nephropathy: NO: 685 (77.1%). Conclusions: Of the patients evaluated, most are women, average age 58. More than 5 years of diagnosis, with family history. Good to regular metabolic control. Treated with oral drugs, they perform self-monitoring. With risk factors, mostly treated. More than 70% do not present cardiovascular disease or microangiopathic complications. Cancer in 2%, being of breast, more frequent.
VL  - 8
IS  - 2
ER  -

Copy | Download

Author Information

Claudia Karina Koleff

Endocrinology, Consulting Room Pellegrini, Chaco, Argentina
Jorgelina Valeria Llense

Nutrition and Diabetes, Hospital René Favaloro, Misiones, Argentina
Sandra Kremmer

Medical Clinic and Diabetes, Hospital J. R. Vidal, Corrientes, Argentina
Monica de la Cruz

Medical Clinic and Diabetes, Hospital J. R. Vidal, Corrientes, Argentina
Verónica de la Vega

Diabetes and Nutrition, Dialysis Center, Corrientes, Argentina
Solis Gustavo

Medical Clinic and Diabetes, Sanatorium Frangioli, Chaco, Argentina
Ruiz Diaz Daniel

General Medicine and Diabetes, Consulting Room, Chaco, Argentina
María Cielo Frisone

Endocrinology, Endo Medicine, Chaco, Argentina
Maria Celia Diaz

Nutrition and Diabetes, Hospital J. C. Perrando, Chaco, Argentina
Laura Martinez

General Medicine, New Formosa Health Center, Formosa, Argentina
Irene Ojeda Damico

Internal Medicine and Nutrition, Santa María del Sur Clinic, Corrientes, Argentina
Gabriela Alegre

Family Medicine, El Colorado Clinic, Formosa, Argentina
Elizabeth Mendez

Medical Clinic and Diabetes, Acute Teaching Hospital Dr. Ramón Madariaga, Misiones, Argentina
Elida Beatriz Romero

Medical Clinic, Diabetes and Obesity, High Complexity Hospital, Formosa, Argentina
Teresita Sosa Cabral

School of Medicine, National University of the Northeast, Corrientes, Argentina
Medeot Rech Maité

School of Medicine, National University of the Northeast, Corrientes, Argentina

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Claudia Karina Koleff, Jorgelina Valeria Llense, Sandra Kremmer, Monica de la Cruz, Verónica de la Vega, et al. (2022). Clinical Characteristics of Patients with Diabetes 2 Usually Treated in a Specialized Clinic, from the NEA/SAD Chapter. International Journal of Clinical and Experimental Medical Sciences, 8(2), 24-31. https://doi.org/10.11648/j.ijcems.20220802.12

Copy | Download

ACS Style

Claudia Karina Koleff; Jorgelina Valeria Llense; Sandra Kremmer; Monica de la Cruz; Verónica de la Vega, et al. Clinical Characteristics of Patients with Diabetes 2 Usually Treated in a Specialized Clinic, from the NEA/SAD Chapter. Int. J. Clin. Exp. Med. Sci. 2022, 8(2), 24-31. doi: 10.11648/j.ijcems.20220802.12

Copy | Download

AMA Style

Claudia Karina Koleff, Jorgelina Valeria Llense, Sandra Kremmer, Monica de la Cruz, Verónica de la Vega, et al. Clinical Characteristics of Patients with Diabetes 2 Usually Treated in a Specialized Clinic, from the NEA/SAD Chapter. Int J Clin Exp Med Sci. 2022;8(2):24-31. doi: 10.11648/j.ijcems.20220802.12

Copy | Download

@article{10.11648/j.ijcems.20220802.12,
  author = {Claudia Karina Koleff and Jorgelina Valeria Llense and Sandra Kremmer and Monica de la Cruz and Verónica de la Vega and Solis Gustavo and Ruiz Diaz Daniel and María Cielo Frisone and Maria Celia Diaz and Laura Martinez and Irene Ojeda Damico and Gabriela Alegre and Elizabeth Mendez and Elida Beatriz Romero and Teresita Sosa Cabral and Medeot Rech Maité},
  title = {Clinical Characteristics of Patients with Diabetes 2 Usually Treated in a Specialized Clinic, from the NEA/SAD Chapter},
  journal = {International Journal of Clinical and Experimental Medical Sciences},
  volume = {8},
  number = {2},
  pages = {24-31},
  doi = {10.11648/j.ijcems.20220802.12},
  url = {https://doi.org/10.11648/j.ijcems.20220802.12},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijcems.20220802.12},
  abstract = {Introduction: Diabetes is a public health problem. The need arises to know the clinical situation and pharmacological treatment of type 2 diabetic patients, in the Diabetes clinic of the different provinces that constitute the NEA /SAD chapter. Objectives: In patients with Diabetes 2, attended in NEA clinics, in: December 2019, January and February 2020: To know: - sex. - Average age – Evolution time and family history in first degree, of Diabetes. - Metabolic control by HbA1c (last 2). -Pharmacological treatment and self-monitoring. - Cancer frequency and location. - Presence of: Risk factors (Overweight / Obesity, hypertension, dyslipemia, hyperuricemia) and treatment. Chronic complications. Materials and Methods: Observational, descriptive, transversal and prospective study. Consecutive sample of patients with Diabetes 2, > 18 years. Criteria: Inclusion: More than one year of diagnosis and attendance at the clinic. Exclusion: Acute intercurrences. Data were loaded into a spreadsheet. Descriptive analysis of the variables was performed. Results: 888 patients. Average age 58 years. Female 465 (52%), Male 423 (48%). Years of diagnosis:  10: 302 (34%). Family history: YES 445 (50%). HbA1c: 8% bad: 243 (27%). Medication: Insulin: 142 (16%), Oral drugs plus insulin: 226 (25%), Oral drugs: 520 (59%); single drug; 214 (24%), combined; 306 (35%). Self-monitoring: NO: 165 (19%). Cancer: NO: 870 (98%). Normal weight: 256 (29%). Hypertension: YES: 641 (72.1%), treated yes: 558 (62.8%), no 83 (9.3%). Dyslipemias: YES: 475 (53%), treated yes: 342 (38.5%), no 133 (15%). Hyperuricemia: NO: 784 (88.3%). Cardiovascular disease: NO: 667 (75%). Retinopathy: NO: 650 (73%). Peripheral neuropathy: NO: 667 (75.1%). Nephropathy: NO: 685 (77.1%). Conclusions: Of the patients evaluated, most are women, average age 58. More than 5 years of diagnosis, with family history. Good to regular metabolic control. Treated with oral drugs, they perform self-monitoring. With risk factors, mostly treated. More than 70% do not present cardiovascular disease or microangiopathic complications. Cancer in 2%, being of breast, more frequent.},
 year = {2022}
}

Copy | Download

TY  - JOUR
T1  - Clinical Characteristics of Patients with Diabetes 2 Usually Treated in a Specialized Clinic, from the NEA/SAD Chapter
AU  - Claudia Karina Koleff
AU  - Jorgelina Valeria Llense
AU  - Sandra Kremmer
AU  - Monica de la Cruz
AU  - Verónica de la Vega
AU  - Solis Gustavo
AU  - Ruiz Diaz Daniel
AU  - María Cielo Frisone
AU  - Maria Celia Diaz
AU  - Laura Martinez
AU  - Irene Ojeda Damico
AU  - Gabriela Alegre
AU  - Elizabeth Mendez
AU  - Elida Beatriz Romero
AU  - Teresita Sosa Cabral
AU  - Medeot Rech Maité
Y1  - 2022/04/26
PY  - 2022
N1  - https://doi.org/10.11648/j.ijcems.20220802.12
DO  - 10.11648/j.ijcems.20220802.12
T2  - International Journal of Clinical and Experimental Medical Sciences
JF  - International Journal of Clinical and Experimental Medical Sciences
JO  - International Journal of Clinical and Experimental Medical Sciences
SP  - 24
EP  - 31
PB  - Science Publishing Group
SN  - 2469-8032
UR  - https://doi.org/10.11648/j.ijcems.20220802.12
AB  - Introduction: Diabetes is a public health problem. The need arises to know the clinical situation and pharmacological treatment of type 2 diabetic patients, in the Diabetes clinic of the different provinces that constitute the NEA /SAD chapter. Objectives: In patients with Diabetes 2, attended in NEA clinics, in: December 2019, January and February 2020: To know: - sex. - Average age – Evolution time and family history in first degree, of Diabetes. - Metabolic control by HbA1c (last 2). -Pharmacological treatment and self-monitoring. - Cancer frequency and location. - Presence of: Risk factors (Overweight / Obesity, hypertension, dyslipemia, hyperuricemia) and treatment. Chronic complications. Materials and Methods: Observational, descriptive, transversal and prospective study. Consecutive sample of patients with Diabetes 2, > 18 years. Criteria: Inclusion: More than one year of diagnosis and attendance at the clinic. Exclusion: Acute intercurrences. Data were loaded into a spreadsheet. Descriptive analysis of the variables was performed. Results: 888 patients. Average age 58 years. Female 465 (52%), Male 423 (48%). Years of diagnosis:  10: 302 (34%). Family history: YES 445 (50%). HbA1c: 8% bad: 243 (27%). Medication: Insulin: 142 (16%), Oral drugs plus insulin: 226 (25%), Oral drugs: 520 (59%); single drug; 214 (24%), combined; 306 (35%). Self-monitoring: NO: 165 (19%). Cancer: NO: 870 (98%). Normal weight: 256 (29%). Hypertension: YES: 641 (72.1%), treated yes: 558 (62.8%), no 83 (9.3%). Dyslipemias: YES: 475 (53%), treated yes: 342 (38.5%), no 133 (15%). Hyperuricemia: NO: 784 (88.3%). Cardiovascular disease: NO: 667 (75%). Retinopathy: NO: 650 (73%). Peripheral neuropathy: NO: 667 (75.1%). Nephropathy: NO: 685 (77.1%). Conclusions: Of the patients evaluated, most are women, average age 58. More than 5 years of diagnosis, with family history. Good to regular metabolic control. Treated with oral drugs, they perform self-monitoring. With risk factors, mostly treated. More than 70% do not present cardiovascular disease or microangiopathic complications. Cancer in 2%, being of breast, more frequent.
VL  - 8
IS  - 2
ER  -

Copy | Download